Intercept Pharmaceuticals, Inc., founded in 2002, is an American biopharmaceutical company dedicated to developing novel synthetic bile acid analogs for the treatment of chronic liver diseases. Their core mission is to address unmet medical needs in conditions such as primary biliary cholangitis (PBC), non-alcoholic steatohepatitis (NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis, and bile acid diarrhea. The company focuses on innovative therapies that aim to improve the lives of patients with these serious liver conditions.

Notable figures associated with Intercept Pharmaceuticals include prominent researchers and industry leaders who have significantly contributed to its growth. The company has secured substantial investments from leading venture capital firms and has achieved key milestones, such as receiving FDA approval for their flagship drug, Ocaliva, for the treatment of PBC. Intercept's impact is evident in its pioneering work in liver disease therapeutics, positioning it as a leader in the biopharmaceutical sector focused on liver health.